Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | KLK1 | P06870 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792825 | 1.00 | CYP1A2 (0.55) | CYP1A2CYP2A6MTNR1AHTR2AF2 | |
| Ethane SCHEMBL12612037 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2A6MTNR1AHTR2AF2 | |
| Hydrochloric Acid SCHEMBL10993696 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2A6MTNR1AHTR2AF2 | |
| Sulfuric Acid SCHEMBL9250308 | 0.90 | MTNR1A (0.55) | MTNR1AHTR2AALDH1A1KDM4EMEN1 | |
| SCHEMBL5746405 | 0.87 | CYP1A2 (0.55) | CYP1A2CYP2A6MTNR1AHTR2AF2 | |
| SCHEMBL5747140 | 0.87 | CYP1A2 (0.55) | CYP1A2CYP2A6MTNR1AHTR2AF2 | |
| Sulfuric Acid SCHEMBL9480703 | 0.86 | MTNR1A (0.51) | MTNR1AHTR2AALDH1A1KDM4EMEN1 | |
| SCHEMBL30881789 | 0.85 | CYP1A2 (0.55) | CYP1A2CYP2A6MTNR1AALDH1A1CYP3A4 | |
| SCHEMBL1806698 | 0.85 | CYP1A2 (0.55) | CYP1A2CYP2A6MTNR1AALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL9640549 | 0.83 | CYP1A2 (0.53) | CYP1A2CYP2A6MTNR1AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5635582-A | Magnetic copolymer, a method of manufacture and applications thereof | ALCATEL ALSTHOM COMPAGNIE GENERALE D'ELECTRICITE (FR) | 1997-06-03 | — | — | US | claimed |
| EP-0354093-B1 | Piperazine derivatives and process for their preparation | SYNTHELABO (FR) | 1993-12-22 | — | — | EP | claimed |
| US-20240182503-A1 | MACROCYCLE COMPLEMENT FACTOR B INHIBITORS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| CN-117865878-A | Chiral indoline-3-one derivative and preparation method thereof | 郑州大学 | 2024-04-12 | — | — | CN | disclosed |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4277982-A1 | MACROCYCLE COMPLEMENT FACTOR B INHIBITORS | Alexion Pharmaceuticals, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-116848238-A | Macrocyclic complement factor B inhibitors | 阿雷克森制药公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-4167982-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230117271-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-5143916-A | Hypotensive agents | ADIR ET COMPAGNIE (FR) | 1992-09-01 | — | — | US | disclosed |
| US-5114816-A | RADIATION-SENSITIVE COMPOUNDS, RADIATION-SENSITIVE MIXTURE PREPARED THEREWITH AND COPYING MATERIAL | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-05-19 | — | — | US | disclosed |
| EP-0434561-A2 | 1-Naphthyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-06-26 | — | — | EP | disclosed |
| US-5010079-A | Treatment of psychological disorders | SYNTHELABO (FR) | 1991-04-23 | — | — | US | disclosed |
| US-4963680-A | INTERMEDIATES FOR THERAPEUTIC DRUGS | SYNTHELABO (FR) | 1990-10-16 | — | — | US | disclosed |
| EP-0006217-B1 | SUBSTITUTED AMINO ACIDS, THEIR USE AND PREPARATION, AND COMPOSITIONS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-03-31 | — | — | EP | disclosed |
| US-4243678-A | GASTROINTESTINAL DISORDERS, LIVER DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1981-01-06 | — | — | US | disclosed |
| EP-0006217-A1 | Substituted amino acids, their use and preparation, and compositions containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1980-01-09 | — | — | EP | disclosed |
| US-4008326-A | INCREASING PRODUCTION OF PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | CYP1A2 4522/4885CYP2A6 4025/4885MTNR1A 3499/4885 |
| US-20240182503-A1 | MACROCYCLE COMPLEMENT FACTOR B INHIBITORS | CFB, CFH, C9 | CYP1A2 3979/4885CYP2A6 4125/4885MTNR1A 4749/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | CYP1A2 4522/4885CYP2A6 4025/4885MTNR1A 3499/4885 |
| US-20230117271-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, ODC1 | CYP1A2 321/4885CYP2A6 1962/4885MTNR1A 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.